Literature DB >> 12725868

Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence.

C Allison1, J A Pratt.   

Abstract

Knowledge of the neural mechanisms underlying the development of benzodiazepine (BZ) dependence remains incomplete. The gamma-aminobutyric acid (GABA(A)) receptor, being the main locus of BZ action, has been the main focus to date in studies performed to elucidate the neuroadaptive processes underlying BZ tolerance and withdrawal in preclinical studies. Despite this intensive effort, however, no clear consensus has been reached on the exact contribution of neuroadaptive processes at the level of the GABA(A) receptor to the development of BZ tolerance and withdrawal. It is likely that changes at the level of this receptor are inadequate in themselves as an explanation of these neuroadaptive processes and that neuroadaptations in other receptor systems are important in the development of BZ dependence. In particular, it has been hypothesised that as part of compensatory mechanisms to diazepam-induced chronic enhancement of GABAergic inhibition, excitatory mechanisms (including the glutamatergic system) become more sensitive [Behav. Pharmacol. 6 (1995) 425], conceivably contributing to BZ tolerance development and/or expression of withdrawal symptoms on cessation of treatment, including increased anxiety and seizure activity. Glutamate is a key candidate for changes in excitatory transmission mechanisms and BZ dependence, (1) since there are defined neuroanatomical relationships between glutamatergic and GABAergic neurons in the CNS and (2) because of the pivotal role of glutamatergic neurotransmission in mediating many forms of synaptic plasticity in the CNS, such as long-term potentiation and kindling events. Thus, it is highly possible that glutamatergic processes are also involved in the neuroadaptive processes in drug dependence, which can conceivably be considered as a form of synaptic plasticity. This review provides an overview of studies investigating changes in the GABAergic and glutamatergic systems in the brain associated with BZ dependence, with particular attention to the possible differential involvement of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors in these processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12725868     DOI: 10.1016/s0163-7258(03)00029-9

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  27 in total

1.  Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; S Randall; E Harris; R Maan; T Roth
Journal:  J Psychopharmacol       Date:  2011-10-16       Impact factor: 4.153

Review 2.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

3.  Differential effects of GABAB autoreceptor activation on ethanol potentiation of local and lateral paracapsular GABAergic synapses in the rat basolateral amygdala.

Authors:  Yuval Silberman; Olusegun J Ariwodola; Jeff L Weiner
Journal:  Neuropharmacology       Date:  2009-01-21       Impact factor: 5.250

4.  Calcium/calmodulin-dependent protein kinase II mediates hippocampal glutamatergic plasticity during benzodiazepine withdrawal.

Authors:  Guofu Shen; Bradley J Van Sickle; Elizabeth I Tietz
Journal:  Neuropsychopharmacology       Date:  2010-05-05       Impact factor: 7.853

5.  βCCT, an antagonist selective for α(1)GABA(A) receptors, reverses diazepam withdrawal-induced anxiety in rats.

Authors:  Jovana Divljaković; Marija Milić; Ojas A Namjoshi; Veera V Tiruveedhula; Tamara Timić; James M Cook; Miroslav M Savić
Journal:  Brain Res Bull       Date:  2012-11-10       Impact factor: 4.077

6.  Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.

Authors:  John J Mariani; Robert J Malcolm; Agnieszka K Mamczur; Jean C Choi; Ronald Brady; Edward Nunes; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2016-03-10       Impact factor: 3.829

Review 7.  Tolerance to allopregnanolone with focus on the GABA-A receptor.

Authors:  Sahruh Turkmen; Torbjorn Backstrom; Goran Wahlstrom; Lotta Andreen; Inga-Maj Johansson
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

Review 8.  Non-pharmacological factors that determine drug use and addiction.

Authors:  Serge H Ahmed; Aldo Badiani; Klaus A Miczek; Christian P Müller
Journal:  Neurosci Biobehav Rev       Date:  2018-09-01       Impact factor: 8.989

Review 9.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

Review 10.  Benzodiazepine dependence and its treatment with low dose flumazenil.

Authors:  Sean David Hood; Amanda Norman; Dana Adelle Hince; Jan Krzysztof Melichar; Gary Kenneth Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.